Core Insights - Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies aimed at restoring vision and preventing blindness in patients with inherited retinal diseases (IRDs) [4] Company Overview - The company is developing durable, one-time treatments that target the underlying genetic causes of severe retinal disorders [4] - Opus Genetics has a pipeline that includes seven AAV-based programs, with key candidates such as OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration [4] - The company is also advancing Phentolamine Ophthalmic Solution 0.75%, which is an approved therapy for pharmacologically induced mydriasis, with potential additional indications in presbyopia and low-light visual disturbances following keratorefractive surgery [4] Upcoming Conferences - Leadership team members will participate in several conferences, including the Collaborative Community on Ophthalmic Innovation (CCOI) and the Asia-Pacific Academy of Ophthalmology Congress (APAO) from February 3-8, 2026, in Hong Kong [2][5] - The company will engage with the global ophthalmology community to discuss advances in gene therapy and evolving strategies for treating inherited retinal disorders [5] - Chris Ernst, Chief Technology Officer, will present on building scalable viral vector manufacturing models on February 11, 2026, in San Diego, CA [5] - Mark Pennesi, M.D., Ph.D., will present preliminary results from a Phase 1b/2a clinical study of OPGx-BEST1 gene therapy on February 27, 2026, in San Diego, CA [5]
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026